Archer-1 dokumentasjonen fra Nanov ble analysert av selskapet og ligger på deres hjemmesider, men det kan være god grunn til å gjenta nå. Det er denne nærmest fysisk betingede økningen av CD20 som gjør at det bør kunne være høye forventninger til kohort 2 i Archer-1. Det er vel nærmest utelukket at en slik virkning plutselig skal kunne forsvinne i kohort 2? Legg også merke til at levetiden for mus i de prekliniske forsøkene øket med 5 GANGER, og det sammenlignet med vanlig rituximab-behandling, dvs. standard SOC-behandling. Siden dette er fysikk og i mindre grad biologi, viste resultatene seg konsistente i forsøk på mennesker, slik vi så i kohort 1. Det bør i utgangspunktet også ha samme gjennomslag i kohort 2, selv om forsøksantallet er lavt. Resultatene i form av reduksjon av krefttumorene bør også være rel. uavhengig av pasientens øvrige helse.
Spesielt flg. ordlyd er det verdt å merke seg: “Betalutin® was found to substantially increase CD20 expression and rituximab binding to rituximab-resistant Raji2R cells and to increase rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay.”
08.10.2020 08:00
Oslo, Norway, 8 October 2020
Nordic Nanovector ASA (OSE: NANO) announces that its preclinical study investigating the ability of Betalutin® (177Lu-lilotomab satetraxetan) to reverse rituximab-resistance in disease models of non-Hodgkin’s lymphoma (NHL) has been published in the October 2020 issue of The Journal of Nuclear Medicine (M. Malenge et al*).
NHL is the most common blood cancer and has a high mortality rate. The CD20-targeting monoclonal antibody immunotherapy rituximab was approved for treatment of NHL more than 20 years ago and is the current standard of care. However, many patients eventually develop resistance against rituximab, which is often associated with changes (a decrease) in expression of the CD20 antigen on NHL cells.
The study found that:
Betalutin® (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.
The median survival time of mice treated with this combination doubled when compared to survival of mice given Betalutin® monotherapy and was five times longer than for mice given rituximab monotherapy.
In NHL cell lines, Betalutin® was found to substantially increase CD20 expression and rituximab binding to rituximab-resistant Raji2R cells and to increase rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay.
“This work is potentially very important, as it could provide a welcome treatment option for the large pool of NHL patients who have become resistant to rituximab. If those patients receive an injection of Betalutin®, they could be treated again with rituximab and have an improved response,” said Dr Jostein Dahle, Chief Scientific Officer of Nordic Nanovector. “In a Phase 1b clinical trial, a 100 percent complete response rate was achieved in the first group of patients treated with Betalutin® followed by rituximab. Achieving a complete response is very important as it usually correlates with an improved duration of response and overall survival.”
Dr Dahle continued, “Combination treatments are the future for cancer therapy. By exploring strategies with radioimmunotherapy together with other drugs, nuclear medicine may play an important role in lymphoma therapy.”
) så den kjøper jeg 
